Safety Study of Levocetirizine Oral Solution for Japanese Pediatrics

NCT01563081 | Completed Phase 3 Results

• 1 other identifier: 116455
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 7

Brief Summary

To evaluate the safety of treatment with levocetirizine oral solution in pediatric patients aged form 6 months to 2 years old with allergic rhinitis or pruritus associated with the skin diseases.

Conditions

Rhinitis

Keywords

Allergic rhinitis; Pediatric; Pruritus; Levocetirizine

Outcome Measures

Primary Outcomes (1)

• Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (AEs)

  A non-serious AE is defined as any untoward medical occurrence in a participant/clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse, or misuse. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is a possible drug-induced liver injury. For a list of all SAEs/non-serious AEs occurring at a frequency of \>=5%, please see the SAE/non-serious AE module of this record.

  up to Week 2/Early Withdrawal (EW)

Secondary Outcomes (4)

• Number of Participants With the Indicated Change From the First Day of Treatment in Allergic Rhinitis and Pruritis Associated With Skin Diseases at Weeks 1 and 2/EW, as Assessed by the Investigator/Sub-investigator Based on Legal Representative Impression

  First day of treatment; Weeks 1 and 2/Early Withdrawal

• Number of Participants With the Indicated Change From the First Day of Treatment in Nasal Symptoms and Pruritis Associated With Skin Diseases at Weeks 1 and 2/Early Withdrawal, as Assessed by the Investigator or Sub-investigator

  First day of treatment; Weeks 1 and 2/Early Withdrawal

• Number of Participants Categorized With the Indicated Pruritis Severity on the First Day of Treatment and at Weeks 1 and 2/Early Withdrawal

  First day of treatment; Weeks 1 and 2/Early Withdrawal

• Cmax and Cmin of Levocetirizine in Plasma

  Weeks 1 and 2/Early Withdrawal

Study Arms (1)

Levocetirizine

EXPERIMENTAL

Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution

Drug: Levocetirizine

Interventions

Levocetirizine DRUG

Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered once daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning to infants aged between 6 months and 1 year old

Levocetirizine

Eligibility Criteria

• Age: 6 Months - 23 Months
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Outpatients
• Either boys or girls are acceptable.
• Pediatric patients ranging from 6 months to 2 years in age at the time of initiation of the treatment in clinical trial
• Pediatric patients who have at least one of the symptoms associated with allergic rhinitis including rhinorrhea, nasal congestion and sneezing, and require at least 2-week treatment with antihistamine drugs, or those who suffer from pruritus associated with the following diseases and require at least 2-week treatment with antihistamine drugs (- Chronic urticaria, - Eczema/dermatitis group: atopic dermatitis etc. \[A diagnosis of atopic dermatitis is made in accordance with the "Definition/Diagnostic Criteria of Atopic Dermatitis, - Prurigo group: acute prurigo (strophulus, urticaria-like lichen, etc.), subacute prurigo, chronic prurigo (nodular prurigo etc.), - Pruritus cutaneous: systemic pruritus cutaneous, local pruritus cutaneous)
• Pediatric patients with QTc interval below 450 msec. QTc interval shall be below 480 msec in the pediatric patients with bundle branch block at screening (A judgment shall be made according to the QTc interval based on ECG result corresponding to one heart beat or the QTc interval based on the mean of ECG results corresponding to 3 heart beats.)
• AST\<2×upper limit of normal, ALT\<2×upper limit of normal, alkaline phosphatase≤1.5×upper limit of normal, bilirubin≤1.5×upper limit of normal at screening (The serum bilirubin shall be fractioned and the direct bilirubin shall be below 35%. In this case, the free bilirubin level exceeding 1.5 times the upper limit of normal is acceptable.)
• Pediatric patients whose parents (persons with parental authority or guardians) shall submit written informed consent
• Pediatric patients whose parents (persons with parental authority or guardians) shall fill the medication diaries

You may not qualify if:

• Pediatric patients whose body weight is above or below the infantile growth curves shown in the infant body growth investigation report in 2011 \[MHLW, 2011\]
• Pediatric patients breast-fed by mothers who take any antihistamine drugs during the study period
• Pediatric patients who received systemic adrenocorticosteroids within 28 days before Visit 2
• Pediatric patients who are currently treated or planned to have immunotherapy initiated during the study period
• Pediatric patients who had abnormal laboratory results that were unrelated to allergic disorders \[These patients can be enrolled if the investigator (or sub-investigator) judges that their enrolment poses no clinical problem.\]
• Pediatric patients who require application of adrenocorticosteroids for external use that are classified as "strongest," "very strong" or "strong"
• Pediatric patients who suffer from asthma as a complication and require treatment with adrenocorticosteroids (including adrenocorticosteroid combinations)
• Pediatric patients with the history of convulsion, febrile convulsion or sleep apnea
• Pediatric patients whose brothers or sisters have history of sleep apnea or sudden infant death syndrome
• Pediatric patients with history of allergy or hypersensitivity to the ingredients of levocetirizine hydrochloride preparation or piperazine derivatives such as hydroxyzine, cetirizine, cyclizine
• Pediatric patients with history of drug hypersensitivity
• Pediatric patients who are considered inappropriate as the subjects of this clinical trial because of liver diseases, renal diseases, heart diseases or other complications that pose clinical problem
• Pediatric patients whose parents are minors
• Infants who belong to children's institutions
• Pediatric patients who participated in other clinical trials for 6 months before enrolment or those who intend to participate in other clinical trials during the clinical trial period.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (7)

GSK Investigational Site

Chiba, 260-0001, Japan

Location

GSK Investigational Site

Tokyo, 136-0073, Japan

Location

GSK Investigational Site

Tokyo, 154-0002, Japan

Location

GSK Investigational Site

Tokyo, 154-0017, Japan

Location

GSK Investigational Site

Tokyo, 157-0066, Japan

Location

GSK Investigational Site

Tokyo, 158-0094, Japan

Location

GSK Investigational Site

Tokyo, 176-0012, Japan

Location

MeSH Terms

Conditions

Rhinitis; Rhinitis, Allergic; Pruritus

Interventions

levocetirizine

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Infections; Nose Diseases; Respiratory Tract Diseases; Otorhinolaryngologic Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Skin Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: GSK Response Center
• Organization: GlaxoSmithKline

866-435-7343

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 15, 2012
• First Posted: March 26, 2012
• Study Start: April 1, 2012
• Primary Completion: August 1, 2012
• Study Completion: August 1, 2012
• Last Updated: February 28, 2017
• Results First Posted: June 3, 2013

Record last verified: 2017-01

Locations

JP (7)